drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody
drug_description
Fully human IgG1 monoclonal antibody targeting CD38, administered by IV infusion. Binds CD38 on antibody-secreting plasma cells and other CD38+ immune cells, inducing depletion via Fc-mediated cytotoxicity (ADCC, CDC, ADCP) and apoptosis to reduce donor-specific antibodies and humoral alloimmunity driving AMR.
nci_thesaurus_concept_id
C97954
nci_thesaurus_definition
A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Felzartamab specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC) and may eventually lead to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.
drug_mesh_term
felzartamab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
Fully human IgG1 anti-CD38 monoclonal antibody that binds CD38 on plasma cells and other CD38+ immune cells and depletes them via Fc-mediated effector functions (ADCC, CDC, ADCP) and apoptosis, thereby reducing donor-specific antibodies and humoral alloimmunity.
drug_name
Felzartamab
nct_id_drug_ref
NCT06685757